Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality

By Pfützner Andreas   Forst Thomas  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 4, 2006-03 ,pp. : 463-476

Informa Healthcare

Access to resources Recommend Favorite

Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?

By  

Current Pharmaceutical Design, Vol. 15, Iss. 27, 2009-09 ,pp. : 3179-3192

Bentham Science Publishers

Access to resources Recommend Favorite

Hypoglycaemia with Oral Antidiabetic Drugs: Results from Prescription-Event Monitoring Cohorts of Rosiglitazone, Pioglitazone, Nateglinide and Repaglinide

By Vlckova Veronika   Cornelius Victoria   Kasliwal Rachna   Wilton Lynda   Shakir Saad A.W.  

Drug Safety, Vol. 32, Iss. 5, 2009-01 ,pp. : 409-418

Adis International

Access to resources Recommend Favorite

Cardiovascular Risk Factors Associated with Insulin Resistance: Effects of Oral Antidiabetic Agents

By Granberry Mark C.   Fonseca Vivian A.  

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 3, 2005-01 ,pp. : 201-209

Adis International

Access to resources Recommend Favorite

Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms

By Pacanowski Michael A   Hopley Charles W   Aquilante Christina L  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 5, 2008-05 ,pp. : 529-544

Informa Healthcare

Access to resources Recommend Favorite